Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
NCT02392572 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2026-08-20 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participants” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-13Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03808610)
- 2026-04-27Also stopped (terminated): M.D. Anderson Cancer Center, Ponatinib + Venetoclax (NCT05268003)
- 2026-04-21Phase 3 first posted: Fujian Medical University Union Hospital, PD-1 Inhibitors (NCT07541755)
- 2026-02-25Results posted on the registry: ECOG-ACRIN Cancer Research Group, Venetoclax + Vincristine Liposomal (NCT03504644)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision